Mogamulizumab (KW0761), a defucosylated monoclonal antibody (mAb) specific for human CCR4, has been approved for treatment of CCR4+ CTCL patients in Japan and the United States (Kim et al., 2018). This evidence concerns the gene CCR4 and primary cutaneous T-cell non-Hodgkin lymphoma.